Revatio® (sildenafil citrate): Safety Information regarding Revatio® tablets for the treatment of pulmonary arterial hypertension (PAH)

User Rating: 0 / 5

Star InactiveStar InactiveStar InactiveStar InactiveStar Inactive
 

Date: 07 October 2014

Description: A Direct Healthcare Professional Communication (DHPC) has been approved by NPCB to inform healthcare professionals of new safety information from a clinical trial regarding use of Revatio® for the treatment of pulmonary arterial hypertension (PAH) in paediatric patients.The package insert will be updated by Pfizer (Malaysia) Sdn. Bhd. with this new information. Please refer to the DHPC for full details. This safety issue was also featured in an NPCB publication, Reaksi Drug Safety News January 2015

National Pharmaceutical Regulatory Agency (NPRA)
Lot 36, Jalan Universiti, 46200 Petaling Jaya, Selangor, Malaysia.
  • Email: npra@npra.gov.my
  • Phone: +603-7883 5400
  • Fax: +603-7956 2924, +603-7956 7075

DISCLAIMER

The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

© Copyright 2018 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA